Recipharm has announced the acquisition of Arranta Bio, an advanced therapy CDMO, and Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners.
The acquisition of Arranta Bio forms a cornerstone of Recipharm’s strategy to provide innovative drug developers in the bio